NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES)

Volume 7 Issue 2 Page 90-94, 2026



ONLINE ISSN:2992-5819 PRINT ISSN:2992-6149

Open Access



https://doi.org/10.59298/NIJSES/2026/72.9094

# Organelle-Targeted Nanotechnology for Selective Induction of Cancer Cell Death

**Nabuuma Ruth Nambi**

**Department of Pharmacy Kampala International University Uganda**
**Email: nambi.nabuuma@studwc.kiu.ac.ug**

## ABSTRACT

Selective induction of cancer cell death remains a central goal of modern oncology, yet conventional chemotherapeutics often lack specificity, leading to systemic toxicity and therapeutic resistance. Organelle-targeted nanotechnology has emerged as a powerful strategy to overcome these limitations by directing therapeutic agents precisely to intracellular organelles that govern survival, metabolism, and death signaling. Mitochondria, nucleus, lysosomes, endoplasmic reticulum, and Golgi apparatus each play distinct roles in regulating apoptosis, autophagy, redox balance, and stress responses, making them highly attractive targets for precision cancer therapy. Nanotechnology enables the rational design of nanoscale systems capable of crossing cellular and subcellular barriers, sensing intracellular cues, and releasing therapeutic payloads at defined organellar sites. This review provides a comprehensive analysis of organelle-targeted nanotechnology for selective cancer cell death. We discuss the biological rationale for targeting specific organelles, design principles of organelle-directed nanocarriers, and mechanistic pathways through which localized damage induces apoptosis, ferroptosis, necroptosis, or immunogenic cell death. Current preclinical advances, emerging combinatorial strategies, and translational challenges are critically evaluated. Organelle-targeted nanotherapeutics represent a transformative platform for achieving high therapeutic precision and durable anticancer responses.

**Keywords:** organelle targeting; nanotechnology; cancer cell death; mitochondria; precision oncology

## INTRODUCTION

Cancer cell survival depends on the coordinated function of intracellular organelles that regulate energy production, macromolecular synthesis, stress adaptation, and signaling integration[1, 2]. Malignant transformation is accompanied by profound alterations in organelle structure and function, enabling tumor cells to withstand metabolic stress, evade apoptosis, and resist therapy. These adaptations, while advantageous for cancer progression, also create exploitable vulnerabilities[3, 4]. Targeting organelle-specific processes has therefore emerged as a rational strategy for selectively inducing cancer cell death while sparing normal tissues[5, 6].

Mitochondria are central regulators of intrinsic apoptosis, reactive oxygen species (ROS) production, and bioenergetics. Cancer cells frequently exhibit mitochondrial rewiring characterized by altered membrane potential, dysregulated electron transport, and increased dependence on anti-apoptotic BCL-2 family proteins[7]. These features render mitochondria highly sensitive to perturbations that disrupt membrane integrity or redox balance. Localized mitochondrial damage can trigger cytochrome c release, caspase activation, and irreversible apoptotic commitment[7].

The nucleus represents another critical organelle, as it houses genomic DNA and coordinates replication, transcription, and DNA damage responses. Cancer cells often rely on hyperactive DNA repair pathways to survive genomic instability[8]. Targeted nuclear delivery of DNA-damaging agents or transcriptional inhibitors can overwhelm repair mechanisms, leading to mitotic catastrophe or apoptosis. Importantly, nuclear

targeting enhances drug efficacy by increasing local concentration at the site of action while reducing off-target exposure[9].

Lysosomes function as degradative hubs and regulators of autophagy, nutrient recycling, and cell death signaling. In cancer, lysosomes are frequently enlarged, more acidic, and enriched in proteases, reflecting increased autophagic flux and metabolic demand. Lysosomal membrane permeabilization results in the release of cathepsins and hydrolases into the cytosol, initiating apoptosis or necrosis[10]. These altered lysosomal properties make them particularly susceptible to targeted disruption.



The endoplasmic reticulum (ER) is responsible for protein folding, lipid synthesis, and calcium homeostasis. Tumor cells experience chronic ER stress due to high protein synthesis rates and hypoxic conditions, relying heavily on the unfolded protein response for survival[11]. Excessive or unresolved ER stress can switch adaptive signaling into pro-death pathways mediated by CHOP, calcium overload, and mitochondrial crosstalk. Targeting ER function can therefore selectively push cancer cells beyond their stress tolerance threshold[11].

The Golgi apparatus, though less explored, plays an essential role in protein trafficking and post-translational modification. Disruption of Golgi integrity affects membrane protein localization, secretory signaling, and cell polarity, impairing tumor growth and metastasis. Collectively, these organelles form an interconnected network, and localized injury to one compartment often propagates lethal signals throughout the cell[12].

Despite the promise of organelle-specific targeting, free drugs rarely achieve sufficient intracellular precision due to poor permeability, rapid efflux, and nonspecific distribution. Nanotechnology addresses these challenges by enabling controlled size, surface chemistry, and functionalization, facilitating selective accumulation in tumors and precise subcellular localization[13–15]. Understanding organelle biology and death signaling pathways is therefore foundational to the rational design of organelle-targeted nanotherapeutics.

## 2. Design Principles of Organelle-Targeted Nanotechnology

Organelle-targeted nanotechnology relies on rational engineering of nanoscale systems capable of navigating complex biological barriers, from systemic circulation to intracellular compartments[16]. Key design parameters include particle size, surface charge, shape, and chemical functionality, all of which influence cellular uptake, intracellular trafficking, and organelle localization[17].

One of the most widely exploited strategies is ligand-mediated targeting. Specific peptides, small molecules, or chemical motifs can direct nanoparticles to defined organelles. For example, lipophilic cations preferentially accumulate in mitochondria due to the high negative membrane potential, while nuclear localization sequences enable transport through nuclear pore complexes[18]. Lysosome targeting can be achieved using weakly basic or acid-sensitive moieties that become protonated and trapped within acidic compartments[18].

Stimuli-responsive design further enhances organelle specificity. Nanoparticles can be engineered to respond to pH gradients, redox conditions, enzyme activity, or ionic composition unique to specific organelles. Such responsiveness ensures that payload release or activation occurs only after reaching the intended subcellular destination, minimizing off-target toxicity[19–21].

Material selection is equally critical. Organic nanoparticles, including liposomes, polymeric nanoparticles, and peptide-based assemblies, offer high biocompatibility and functional versatility. Inorganic systems, such as metallic or silica-based nanoparticles, provide unique optical, thermal, or catalytic properties that can be harnessed for photothermal or chemodynamic therapy. Hybrid systems combine these advantages, enabling multifunctional platforms for diagnosis and therapy[22, 23].

Ultimately, successful organelle-targeted nanotechnology integrates targeting, responsiveness, and therapeutic function into a unified design tailored to specific cancer vulnerabilities.

## 3. Mitochondria-Targeted Nanotechnology for Apoptosis Induction

Mitochondria are central regulators of intrinsic apoptosis and cellular metabolism, making them one of the most attractive intracellular targets for cancer nanotherapy[24]. Cancer cells often exhibit elevated mitochondrial membrane potential, altered redox balance, and metabolic dependence on mitochondrial function, distinguishing them from normal cells. Mitochondria-targeted nanotherapeutics exploit these differences to achieve selective accumulation within tumor mitochondria and induce programmed cell death with high specificity[25].

Nanoparticles designed for mitochondrial targeting commonly incorporate lipophilic cations, such as triphenylphosphonium, or mitochondrial-targeting peptides that respond to membrane potential–driven uptake[14, 22, 23]. These targeting moieties enable nanoparticles to bypass cytosolic dilution and concentrate within the mitochondrial matrix or inner membrane. Once localized, mitochondria-targeted nanotherapeutics initiate apoptosis through multiple synergistic mechanisms. Disruption of mitochondrial membrane potential impairs ATP production and triggers cytochrome c release, activating caspase cascades. Inhibition of oxidative phosphorylation further deprives cancer cells of energy, exacerbating metabolic stress[26].

A prominent mechanism underlying mitochondrial nanotherapy is excessive reactive oxygen species (ROS) generation. Localized ROS production within mitochondria damages mitochondrial DNA, lipids, and respiratory chain proteins, amplifying apoptotic signaling[27]. Because cancer cells often operate near the threshold of oxidative stress, additional ROS generation selectively pushes them toward cell death while sparing normal cells with more robust antioxidant capacity[27].

Some mitochondria-targeted systems deliver pro-apoptotic peptides, BH3 mimetics, or BCL-2 family inhibitors directly to mitochondria. This direct delivery bypasses cytosolic sequestration and drug efflux mechanisms that

frequently confer resistance to conventional therapies[28]. By engaging the apoptotic machinery at its point of origin, these nanotherapeutics overcome intrinsic and acquired resistance pathways.

Mitochondria-targeted photothermal and photodynamic nanotherapies further enhance therapeutic precision[28, 29]. Upon external stimulation with light, these nanoparticles generate localized heat or singlet oxygen specifically within mitochondria, causing catastrophic organelle dysfunction. Spatial confinement of thermal or oxidative damage dramatically increases antitumor efficacy while minimizing collateral injury to surrounding healthy tissues. Collectively, mitochondria-targeted nanotechnology represents a powerful and versatile strategy for inducing apoptosis in resistant and metabolically adapted cancers.



**4. Nuclear-Targeted Nanotechnology and Genomic Catastrophe**

The nucleus is the command center of cellular survival, governing DNA replication, transcription, and epigenetic regulation. Nuclear-targeted nanotechnology seeks to directly disrupt these processes, inducing genomic catastrophe and irreversible loss of proliferative capacity in cancer cells[30]. However, efficient nuclear targeting poses significant challenges, as nanotherapeutics must traverse both the plasma membrane and the nuclear envelope.

To overcome these barriers, nuclear-targeted nanoparticles are often functionalized with nuclear localization sequences, DNA-binding peptides, or ligands that exploit nuclear import pathways. These design features enable selective accumulation of therapeutic payloads within the nucleus. Once delivered, nuclear-targeted nanotherapeutics enhance the efficacy of chemotherapeutic agents, gene-editing tools, and transcriptional inhibitors by concentrating them at their site of action[31].

Localized DNA damage induced by nuclear-targeted nanoparticles leads to replication stress, chromosomal instability, and activation of DNA damage response pathways. By overwhelming repair mechanisms, these systems drive cancer cells toward apoptosis or mitotic catastrophe. Importantly, nuclear targeting circumvents drug resistance associated with efflux pumps and cytoplasmic drug inactivation, enabling sustained genomic insult[32]. Beyond direct cytotoxicity, nuclear-targeted nanotherapeutics can modulate epigenetic regulators and oncogenic transcription programs. Delivery of inhibitors targeting histone modifiers, chromatin remodelers, or transcription factors can reprogram cancer cell identity, inducing differentiation or senescence. Such irreversible growth arrest represents an alternative form of therapeutic success, particularly in tumors that evade apoptosis[33].

By combining precision delivery with potent nuclear effects, nuclear-targeted nanotechnology expands the therapeutic landscape beyond DNA damage toward durable reprogramming of cancer cell fate.

**5. Lysosome- and ER-Targeted Nanotechnology for Stress-Mediated Cell Death**

Lysosomes and the endoplasmic reticulum (ER) are critical regulators of cellular homeostasis, and their dysfunction can trigger potent stress-mediated death pathways[34]. Cancer cells often exhibit enlarged, fragile lysosomes and heightened ER stress, rendering these organelles vulnerable to targeted intervention. Lysosome-targeted nanotechnology exploits the acidic environment and membrane instability of cancer lysosomes[35]. Nanoparticles designed to accumulate in lysosomes can destabilize lysosomal membranes, leading to lysosomal membrane permeabilization and the release of cathepsins into the cytosol. These proteases initiate apoptotic or necrotic pathways independently of mitochondrial signaling, making this strategy particularly effective against apoptosis-resistant tumors[35].

ER-targeted nanotherapeutics induce lethal stress by disrupting protein folding, calcium homeostasis, or lipid synthesis. Sustained ER stress activates pro-death unfolded protein response signaling pathways, including CHOP-mediated apoptosis. ER stress also engages mitochondrial crosstalk, amplifying cell death signals[36].

Integrating lysosomal and ER targeting within a single nanoplatform can synergistically amplify stress responses. Simultaneous disruption of protein homeostasis and degradative pathways overwhelms adaptive mechanisms, driving cancer cells toward irreversible death[36]. These stress-mediated strategies provide alternative routes to eliminate tumors resistant to conventional apoptosis-based therapies.

**6. Multiorganelle Targeting and Immunogenic Cell Death**

Advanced nanotechnologies increasingly focus on multiorganelle targeting strategies that reflect the interconnected nature of intracellular signaling networks. Rather than isolating a single organelle, these systems are designed to induce cascading dysfunction across multiple compartments[36]. For example, nanoparticles may initiate ER stress that propagates to mitochondria, amplifying apoptotic signaling and metabolic collapse.

Multiorganelle targeting enhances therapeutic robustness by limiting the ability of cancer cells to compensate through alternative survival pathways. Sequential or simultaneous targeting of mitochondria, nucleus, lysosomes, and ER creates synergistic stress that overwhelms cellular defenses[37]. Importantly, organelle-targeted nanotherapy can promote immunogenic cell death. Organelle disruption leads to the release of damage-associated molecular patterns, such as mitochondrial DNA, ATP, and calreticulin, which activate dendritic cells and enhance antigen presentation. This immunogenicity bridges direct tumor killing with immune activation[37].

Integration of multiorganelle nanotherapy with immunotherapy represents a promising strategy for durable cancer control. By coupling intracellular catastrophe with immune engagement, these approaches extend therapeutic impact beyond tumor debulking toward long-term immune surveillance and prevention of relapse.

## 7. Conclusion and Future Perspectives

Organelle-targeted nanotechnology represents a paradigm shift in precision cancer therapy by enabling selective, localized induction of cancer cell death. By exploiting organelle-specific vulnerabilities, these systems achieve high efficacy with reduced systemic toxicity. Continued advances in nanomaterial design, intracellular targeting, and understanding of cell death pathways will accelerate clinical translation. Future efforts should emphasize patient stratification, scalable manufacturing, and integration with immuno-oncology. With these advances, organelle-targeted nanotherapeutics are poised to redefine the landscape of selective anticancer treatment.



## REFERENCES


1. Graziani, V., Crosas-Molist, E., George, S.L., Sanz-Moreno, V.: Organelle adaptations in response to mechanical forces during tumour dissemination. Curr. Opin. Cell Biol. 88, 102345 (2024). https://doi.org/10.1016/j.ceb.2024.102345
2. Sneeggen, M., Guadagno, N.A., Progida, C.: Intracellular Transport in Cancer Metabolic Reprogramming. Front. Cell Dev. Biol. 8, (2020). https://doi.org/10.3389/fcell.2020.597608
3. Sharma, A., Boise, L.H., Shanmugam, M.: Cancer Metabolism and the Evasion of Apoptotic Cell Death. Cancers. 11, 1144 (2019). https://doi.org/10.3390/cancers11081144
4. Turlej, E., Domaradzka, A., Radzka, J., Drulis-Fajdasz, D., Kulbacka, J., Gizak, A.: Cross-Talk Between Cancer and Its Cellular Environment—A Role in Cancer Progression. Cells. 14, (2025). https://doi.org/10.3390/cells14060403
5. Akwari, A.Ak., Okoroh, P.N., Aniokete, U.C., Abba, J.N., Uti, D.E.: Phytochemicals as modulators of ferroptosis: a novel therapeutic avenue in cancer and neurodegeneration. Mol. Biol. Rep. 52, 636 (2025). https://doi.org/10.1007/s11033-025-10752-4
6. Dominiak, A., Chełstowska, B., Nowicka, G.: Metabolic Adaptations in Cancer Progression: Optimization Strategies and Therapeutic Targets. Cancers. 17, (2025). https://doi.org/10.3390/cancers17142341
7. Huang, C., Xie, Z., Li, J., Zhang, C.: Mitochondria and tumorigenesis: Molecular basis and therapeutic implications. Genes Dis. 13, 101806 (2026). https://doi.org/10.1016/j.gendis.2025.101806
8. Bacolla, A., Ye, Z., Ahmed, Z., Tainer, J.A.: Cancer mutational burden is shaped by G4 DNA, replication stress and mitochondrial dysfunction. Prog. Biophys. Mol. Biol. 147, 47–61 (2019). https://doi.org/10.1016/j.pbiomolbio.2019.03.004
9. Khazaei Monfared, Y., Heidari, P., Klempner, S.J., Mahmood, U., Parikh, A.R., Hong, T.S., Strickland, M.R., Esfahani, S.A.: DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair. Pharmaceutics. 15, 2761 (2023). https://doi.org/10.3390/pharmaceutics15122761
10. Mahapatra, K.K., Mishra, S.R., Behera, B.P., Patil, S., Gewirtz, D.A., Bhutia, S.K.: The lysosome as an imperative regulator of autophagy and cell death. Cell. Mol. Life Sci. CMLS. 78, 7435–7449 (2021). https://doi.org/10.1007/s00018-021-03988-3
11. Chen, X., Cubillos-Ruiz, J.R.: Endoplasmic reticulum stress signals in the tumour and its microenvironment. Nat. Rev. Cancer. 21, 71–88 (2021). https://doi.org/10.1038/s41568-020-00312-2
12. Vlad, D.-B., Dumitrascu, D.-I., Dumitrascu, A.-L.: Golgi's Role in the Development of Possible New Therapies in Cancer. Cells. 12, 1499 (2023). https://doi.org/10.3390/cells12111499
13. Uti, D.E., Alum, E.U., Atangwho, I.J., Ugwu, O.P.-C., Egbung, G.E., Aja, P.M.: Lipid-based nano-carriers for the delivery of anti-obesity natural compounds: advances in targeted delivery and precision therapeutics. J. Nanobiotechnology. 23, 336 (2025). https://doi.org/10.1186/s12951-025-03412-z
14. Omang, W.A., Bawa, I., Idowu, A.O., Atangwho, I.J., Egbung, G.E.: Theranostic Nanoparticles in Prostate Cancer: Disrupting Hypoxia-Induced Glycolysis by Targeting Hypoxia-Inducible Factor-1 Alpha and Downstream Metabolites. Cancer Med. 15, e71519 (2026). https://doi.org/10.1002/cam4.71519
15. Ntaobeten, E., Obeten, U.N., Bawa, I., Agada, S.A., Ukam, C.I.-O., Egbung, G.E.: Antioxidants in cancer therapy mitigating lipid peroxidation without compromising treatment through nanotechnology. Discov. Nano. 20, 70 (2025). https://doi.org/10.1186/s11671-025-04248-0
16. Soukar, J., Peppas, N.A., Gaharwar, A.K.: Organelle-Targeting Nanoparticles. Adv. Sci. 12, 2411720 (2025). https://doi.org/10.1002/advs.202411720
17. Gonzalez, J.C., Park, K.W., Evans, D.B., Sharma, R., Sahaym, O., Gopalakrishnan, S., Dar, A.I., Valdez, T.A., Sharma, A.: Nano Approaches to Nucleic Acid Delivery: Barriers, Solutions, and Current Landscape. WIREs Nanomedicine Nanobiotechnology. 17, e70010 (2025). https://doi.org/10.1002/wnan.70010
18. Tan, K., Zhang, H., Yang, J., Wang, H., Li, Y., Ding, G., Gu, P., Yang, S., Li, J., Fan, X.: Organelle-oriented nanomedicines in tumor therapy: Targeting, escaping, or collaborating? Bioact. Mater. 49, 291–339 (2025). https://doi.org/10.1016/j.bioactmat.2025.02.040
19. Hou, J., Xue, Z., Chen, Y., Li, J., Yue, X., Zhang, Y., Gao, J., Hao, Y., Shen, J.: Development of Stimuli-Responsive Polymeric Nanomedicines in Hypoxic Tumors and Their Therapeutic Promise in Oral Cancer. Polymers. 17, (2025). https://doi.org/10.3390/polym17081010
20. Lee, H., Rho, W.-Y., Kim, Y.-H., Chang, H., Jun, B.-H.: CRISPR-Cas9 Gene Therapy: Non-Viral Delivery and Stimuli-Responsive Nanoformulations. Molecules. 30, 542 (2025). https://doi.org/10.3390/molecules30030542

21. Yang, J., des Rieux, A., Malfanti, A.: Stimuli-Responsive Nanomedicines for the Treatment of Non-cancer Related Inflammatory Diseases. ACS Nano. 19, 15189–15219 (2025). https://doi.org/10.1021/acsnano.5c00700
22. Janjua, T.I., Cao, Y., Kleitz, F., Linden, M., Yu, C., Popat, A.: Silica nanoparticles: A review of their safety and current strategies to overcome biological barriers. Adv. Drug Deliv. Rev. 203, 115115 (2023). https://doi.org/10.1016/j.addr.2023.115115
23. Shirazi, A.N., Vadlapatla, R., Koomer, A., Nguyen, A., Khoury, V., Parang, K.: Peptide-Based Inorganic Nanoparticles as Efficient Intracellular Delivery Systems. Pharmaceutics. 17, (2025). https://doi.org/10.3390/pharmaceutics17091123
24. Li, Y., Li, X., Wei, L., Ye, J.: Advancements in mitochondrial-targeted nanotherapeutics: overcoming biological obstacles and optimizing drug delivery. Front. Immunol. 15, 1451989 (2024). https://doi.org/10.3389/fimmu.2024.1451989
25. Rout, S.K., Priya, V., Setia, A., Mehata, A.K., Mohan, S., Albratty, M., Najmi, A., Meraya, A.M., Makeen, H.A., Tambuwala, M.M., Muthu, M.S.: Mitochondrial targeting theranostic nanomedicine and molecular biomarkers for efficient cancer diagnosis and therapy. Biomed. Pharmacother. 153, 113451 (2022). https://doi.org/10.1016/j.biopha.2022.113451
26. Du, H., Xu, T., Yu, S., Wu, S., Zhang, J.: Mitochondrial metabolism and cancer therapeutic innovation. Signal Transduct. Target. Ther. 10, 245 (2025). https://doi.org/10.1038/s41392-025-02311-x
27. Zorov, D.B., Juhaszova, M., Sollott, S.J.: Mitochondrial Reactive Oxygen Species (ROS) and ROS-Induced ROS Release. Physiol. Rev. 94, 909–950 (2014). https://doi.org/10.1152/physrev.00026.2013
28. Mukherjee, N., Sheetz, J., Shellman, Y.G.: Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies. Int. J. Mol. Sci. 26, (2025). https://doi.org/10.3390/ijms26209859
29. Patel, P., Mendoza, A., Robichaux, D.J., Wang, M.C., Wehrens, X.H.T., Karch, J.: Inhibition of the Anti-Apoptotic Bcl-2 Family by BH3 Mimetics Sensitize the Mitochondrial Permeability Transition Pore Through Bax and Bak. Front. Cell Dev. Biol. 9, (2021). https://doi.org/10.3389/fcell.2021.765973
30. Mu, H., Dong, W., Chen, L., Li, Q., Xue, B., Xing, Y., Liu, J., Wei, Y., Fan, J., Liang, T., Yang, Y., Yu, S.: Research Progress on Nucleus-Targeting Carbon Nanoparticles for Tumor Imaging and Therapy. Int. J. Nanomedicine. 20, 9695–9721 (2025). https://doi.org/10.2147/IJN.S520205
31. Skowicki, M., Tarvirdipour, S., Kraus, M., Schoenenberger, C.-A., Palivan, C.G.: Nanoassemblies designed for efficient nuclear targeting. Adv. Drug Deliv. Rev. 211, 115354 (2024). https://doi.org/10.1016/j.addr.2024.115354
32. Shah, P., Hobson, C.M., Cheng, S., Colville, M.J., Paszek, M.J., Superfine, R., Lammerding, J.: Nuclear deformation causes DNA damage by increasing replication stress. Curr. Biol. CB. 31, 753-765.e6 (2021). https://doi.org/10.1016/j.cub.2020.11.037
33. Zhang, J., Dai, Q., Park, D., Deng, X.: Targeting DNA Replication Stress for Cancer Therapy. Genes. 7, (2016). https://doi.org/10.3390/genes7080051
34. Vietri, M., Miranda, M.R., Amodio, G., Ciaglia, T., Bertamino, A., Campiglia, P., Remondelli, P., Vestuto, V., Moltedo, O.: The Link Between Endoplasmic Reticulum Stress and Lysosomal Dysfunction Under Oxidative Stress in Cancer Cells. Biomolecules. 15, 930 (2025). https://doi.org/10.3390/biom15070930
35. Tian, X., Shi, A., Yin, H., Wang, Y., Liu, Q., Chen, W., Wu, J.: Nanomaterials Respond to Lysosomal Function for Tumor Treatment. Cells. 11, 3348 (2022). https://doi.org/10.3390/cells11213348
36. Chai, H., Hu, Q., Yao, S., Ma, S., Su, W.: Endoplasmic reticulum stress-mediated programmed cell death in the tumor microenvironment. Cell Death Discov. 11, 559 (2025). https://doi.org/10.1038/s41420-025-02862-6
37. Yang, J., Griffin, A., Qiang, Z., Ren, J.: Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology. Signal Transduct. Target. Ther. 7, 379 (2022). https://doi.org/10.1038/s41392-022-01243-0


**CITE AS: Nabuuma Ruth Nambi (2026). Organelle-Targeted Nanotechnology for Selective Induction of Cancer Cell Death. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES, 7(2):90-94.**
**https://doi.org/10.59298/NIJSES/2026/72.9094**